Literature DB >> 30990348

Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.

Michihiko Aoyama1, Noritaka Hashii1, Wataru Tsukimura2, Kenji Osumi2, Akira Harazono1, Minoru Tada1, Masato Kiyoshi1, Akio Matsuda2, Akiko Ishii-Watabe1.   

Abstract

Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation). Terminal galactose (Gal) residues of Fc-glycans are known to influence effector functions such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity (CDC), but the impact of the G1F isomers (G1aF and G1bF) on the effector functions has not been reported. Here, we prepared four types of glycoengineered anti-CD20 mAbs bearing homogeneous G2F, G1aF, G1bF, or G0F (G2F mAb, G1aF mAb, G1bF mAb, or G0F mAb, respectively), and evaluated their biological activities. Interestingly, G1aF mAb showed higher C1q- and FcγR-binding activities, CDC activity, and FcγR-activation property than G1bF mAb. The activities of G1aF mAb and G1bF mAb were at the same level as G2F mAb and G0F mAb, respectively. Hydrogen-deuterium exchange/mass spectrometry analysis of dynamic structures of mAbs revealed the greater involvement of the terminal Gal residue on the Man α1-6 arm in the structural stability of the CH2 domain. Considering that mAbs interact with FcγR and C1q via their hinge proximal region in the CH2 domain, the structural stabilization of the CH2 domain by the terminal Gal residue on the Man α1-6 arm of Fc-glycans may be important for the effector functions of mAbs. To our knowledge, this is the first report showing the impact of G1F isomers on the effector functions and dynamic structure of mAbs. Abbreviations: ABC, ammonium bicarbonate solution; ACN, acetonitrile; ADCC, antibody-dependent cell-mediated cytotoxicity; C1q, complement component 1q; CDC, complement-dependent cytotoxicity; CQA, critical quality attribute; Endo, endo-β-N-acetylglucosaminidase; FA, formic acid; Fc, crystallizable fragment; FcγR, Fcγ receptors; Fuc, fucose; Gal, galactose; GlcNAc, N-acetylglucosamine; GST, glutathione S-transferase; HER2, human epidermal growth factor receptor 2; HDX, hydrogen-deuterium exchange; HILIC, hydrophilic interaction liquid chromatography; HLB-SPE, hydrophilic-lipophilic balance-solid-phase extraction; HPLC, high-performance liquid chromatography; mAb, monoclonal antibody; Man, mannose; MS, mass spectrometry; PBS, phosphate-buffered saline; SGP, hen egg yolk sialylglycopeptides.

Entities:  

Keywords:  Therapeutic monoclonal antibody; antibody-dependent cell-mediated cytotoxicity; complement-dependent cytotoxicity; galactose; glycoengineering

Mesh:

Substances:

Year:  2019        PMID: 30990348      PMCID: PMC6601563          DOI: 10.1080/19420862.2019.1608143

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  16 in total

Review 1.  Advances in Hydrogen/Deuterium Exchange Mass Spectrometry and the Pursuit of Challenging Biological Systems.

Authors:  Ellie I James; Taylor A Murphree; Clint Vorauer; John R Engen; Miklos Guttman
Journal:  Chem Rev       Date:  2021-09-07       Impact factor: 72.087

Review 2.  Importance and Monitoring of Therapeutic Immunoglobulin G Glycosylation.

Authors:  Yusuke Mimura; Radka Saldova; Yuka Mimura-Kimura; Pauline M Rudd; Roy Jefferis
Journal:  Exp Suppl       Date:  2021

3.  Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies.

Authors:  Michiko Tajiri-Tsukada; Noritaka Hashii; Akiko Ishii-Watabe
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

4.  Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation.

Authors:  Bingchuan Wei; Xuan Gao; Lance Cadang; Saeed Izadi; Peilu Liu; Hui-Min Zhang; Elizabeth Hecht; Jeongsup Shim; Gordon Magill; Juan Rincon Pabon; Lu Dai; Wilson Phung; Elaine Lin; Christopher Wang; Kevin Whang; Sean Sanchez; Jose Oropeza; Julien Camperi; Jennifer Zhang; Wendy Sandoval; Yonghua Taylor Zhang; Guoying Jiang
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

Review 5.  Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.

Authors:  Kevin O Saunders
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

6.  Proteoform-Resolved FcɤRIIIa Binding Assay for Fab Glycosylated Monoclonal Antibodies Achieved by Affinity Chromatography Mass Spectrometry of Fc Moieties.

Authors:  Steffen Lippold; Simone Nicolardi; Manfred Wuhrer; David Falck
Journal:  Front Chem       Date:  2019-10-24       Impact factor: 5.221

7.  The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein.

Authors:  Takuo Suzuki; Noritaka Hashii; Minoru Tada; Akiko Ishii-Watabe
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

8.  Serum immunoglobulin G N-glycome: a potential biomarker in endometrial cancer.

Authors:  Sihan Lin; You Wang; Xinran Wang; Bin Yan; Weihua Lou; Wen Di
Journal:  Ann Transl Med       Date:  2020-06

9.  Clustering and curation of electropherograms: an efficient method for analyzing large cohorts of capillary electrophoresis glycomic profiles for bioprocessing operations.

Authors:  Ian Walsh; Matthew S F Choo; Sim Lyn Chiin; Amelia Mak; Shi Jie Tay; Pauline M Rudd; Yang Yuansheng; Andre Choo; Ho Ying Swan; Terry Nguyen-Khuong
Journal:  Beilstein J Org Chem       Date:  2020-08-27       Impact factor: 2.883

10.  A new approach for identifying positional isomers of glycans cleaved from monoclonal antibodies.

Authors:  Irina Dyukova; Ahmed Ben Faleh; Stephan Warnke; Natalia Yalovenko; Vasyl Yatsyna; Priyanka Bansal; Thomas R Rizzo
Journal:  Analyst       Date:  2021-07-26       Impact factor: 4.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.